Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 2
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Method Reporting with Initials for Transparency (MeRIT) promotes more granularity and accountability for author contributions.
Nakagawa S, Ivimey-Cook ER, Grainger MJ, O'Dea RE, Burke S, Drobniak SM, Gould E, Macartney EL, Martinig AR, Morrison K, Paquet M, Pick JL, Pottier P, Ricolfi L, Wilkinson DP, Willcox A, Williams C, Wilson LAB, Windecker SM, Yang Y, Lagisz M. Nakagawa S, et al. Among authors: williams c. Nat Commun. 2023 Apr 3;14(1):1788. doi: 10.1038/s41467-023-37039-1. Nat Commun. 2023. PMID: 37012240 Free PMC article.
Utility of Serial Transcriptomic Analyses to Characterize the Resistome and to Refine Treatment Selection for Metastatic Colon Cancer: Case Report.
Castro MP, Afshar M, Williams C, Turcat T, Parker D, Gordon E, Zambelli J, McDonald A, Suh C, Baylon S, Biskup S. Castro MP, et al. Among authors: williams c. Clin Colorectal Cancer. 2021 Mar;20(1):96-99. doi: 10.1016/j.clcc.2020.10.003. Epub 2020 Oct 24. Clin Colorectal Cancer. 2021. PMID: 33353848 Free article. No abstract available.
A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study.
Hampel H, Williams C, Etcheto A, Goodsaid F, Parmentier F, Sallantin J, Kaufmann WE, Missling CU, Afshar M. Hampel H, et al. Among authors: williams c. Alzheimers Dement (N Y). 2020 Apr 19;6(1):e12013. doi: 10.1002/trc2.12013. eCollection 2020. Alzheimers Dement (N Y). 2020. PMID: 32318621 Free PMC article.